BioPharma Credit buys back $50 mln shares, reports $72.8 mln profit in first half

BioPharma Credit Plc reported a H1 2025 return on ordinary activities of $72.8 million, a slight increase year-over-year, with net asset value per share rising to $1.0186. However, the share price remained flat at 88.4 cents, widening its discount to NAV to 13.2%. The company actively deployed $144.2 million in new loans and received significant repayments, while returning $89.5 million to shareholders through dividends and $50 million in share repurchases, equivalent to 7.8% of NAV. Its portfolio's 76% exposure to floating interest rates and robust cash position of $213.2 million highlight its strategic positioning and financial flexibility.

Analysis

BioPharma Credit Plc (BPCR) reported a resilient first half for 2025, with a return on ordinary activities rising slightly year-over-year to $72.8 million from $71.8 million. The core tension for investors lies in the divergence between fundamental performance and market valuation; while net asset value (NAV) per share increased to $1.0186 from $0.9963 a year prior, the share price remained static at 88.4 cents, causing the discount to NAV to widen to 13.2%. The company is actively addressing this discount through a $50 million share repurchase program, buying back shares at an average price of 88 cents. Capital management was robust, with $89.5 million returned to shareholders via dividends and buybacks, equivalent to 7.8% of NAV. Notably, the declared half-year dividend of 6.75 cents per share slightly outpaced the net income of 6.33 cents per share. Operationally, the company demonstrated strong portfolio dynamism, deploying $144.2 million in new loans while managing significant repayments and a legal settlement, which boosted its cash position to $213.2 million. A key strategic advantage is the portfolio's structure, with 76% of the loan balance ($685.4 million) tied to floating interest rates, positioning it to benefit from a rising rate environment.

Key Decisions for Investors

• Consider the widening 13.2% discount to NAV as a potential value opportunity, particularly as management is actively executing an accretive share buyback program below the intrinsic value of $1.0186 per share.
• For income-focused investors, the strong capital return program, equivalent to 7.8% of NAV in the first half, is attractive, though the fact that declared dividends slightly exceed net income warrants monitoring.
• Recognize that the portfolio's 76% exposure to floating-rate loans provides a defensive posture against interest rate volatility, while its substantial liquidity, including $213.2 million in cash and a pending $99.5 million repayment, offers significant 'dry powder' for future accretive investments.